Recce Pharmaceuticals CEO talked with Proactive about a key milestone in the company’s infectious disease pipeline—receiving human research ethics approval to build on its phase two clinical trial for R327G in the treatment of diabetic foot infections.
James Graham outlined how this new study focuses specifically on diabetic foot ulcer patients, addressing a major unmet need. “We had a 93% success rate in as little as 14 days,” he noted, highlighting the compound’s efficacy and the decision to expand access for these patients through a dedicated trial arm.
Graham discussed how systemic antibiotics often fail to reach the infection site in such cases due to poor local vasculature, whereas Recce’s topical R327G gel can penetrate deeply and directly. “It’s just the optimum compound for treating these types of bacterial diseases,” he added.
The company will measure long-term efficacy using an FDA-recognised protocol, and is now running two phase three trials—in Indonesia and Australia. Indonesia’s trial is aimed at early revenue generation via diabetic foot ulcer treatment, while Australia’s broader application trial targets the USFDA pathway.
Looking ahead, Graham said, “It’s data, data, data,” as Recce anticipates results from compassionate access dosing and expects two major trial readouts by Q1 next year. These are expected to support licensing and marketing discussions already underway.
Watch the full interview for insights into the next steps and potential global market opportunities for R327G.
Visit Proactive’s YouTube channel for more biotech interviews. Don’t forget to like, subscribe, and turn on notifications so you don’t miss the next update.